Teknova has launched Build-Tek, an AI-powered custom product configurator designed to allow therapeutic and diagnostic developers to create complex custom reagent requests within minutes and move more quickly from preclinical research toward clinical manufacturing.
Build-Tek is the AI-powered evolution of Teknova’s proprietary custom configurator introduced in 2024. Following a beta release during Q2, the company formally launched the platform to help researchers configure complex custom products through a more automated process.
Teknova produces critical reagents used across drug discovery, development and commercialization, including culture media, buffers, cryopreservation products and other materials used in genomics, molecular diagnostics and emerging therapeutic modalities.
The Build-Tek platform is intended to simplify a traditionally complex custom manufacturing workflow by allowing users to configure products rapidly while maintaining a path toward manufacturing requirements as programs advance from research use into clinical development.
The AI rollout comes as Teknova’s core business is showing signs of accelerating. Q2 revenue increased 18% to a company-record $12.2 million. Lab Essentials revenue increased 18% to $9.2 million, while Clinical Solutions revenue also increased 18% to $2.4 million.
Gross margin increased to 40.1% from 38.7%. Net loss narrowed to $3.2 million from $3.6 million, while Adjusted EBITDA loss improved to $0.7 million from $0.8 million.
Cash usage improved significantly. Q2 free cash outflow fell to $0.6 million from $2.3 million a year earlier, while cash used in operating activities declined to $0.5 million from $2.1 million.
Following the quarter, Teknova raised its 2026 revenue guidance to $45 million to $47 million and improved its expected full-year free cash outflow to less than $8 million.
KEY QUOTES:
“We delivered more than $12 million in quarterly revenue for the first time in Teknova’s history, with growth across nearly all of the end markets we serve.”
“These results demonstrate the impact of the investments we’ve made in our commercial organization, state-of-the-art facilities, and manufacturing systems, and strengthen our confidence in our ability to deliver long-term, sustainable growth as the biotech market continues to recover.”
Stephen Gunstream, President And Chief Executive Officer Of Teknova
“We delivered excellent financial results in the second quarter 2026 compared to 2025, including 18% revenue growth and a significant improvement in Free Cash Outflow. We are therefore raising our 2026 revenue guidance to $45-47 million and adjusting down our expectations for full-year Free Cash Outflow to less than $8 million.”
Matt Lowell, Chief Financial Officer Of Teknova
